Free Trial

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$144.40
-1.7%
$151.11
$143.13
$175.97
$347.52B0.557.41 million shs10.49 million shs
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$126.11
-2.6%
$128.31
$99.14
$133.10
$319.41B0.398.00 million shs10.26 million shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$134.08
-1.4%
$128.27
$75.56
$138.28
$601.69B0.434.64 million shs3.14 million shs
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
$503.68
-0.9%
$489.65
$436.38
$554.70
$463.58B0.554.16 million shs2.90 million shs
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.00%-2.87%+0.57%-8.70%-4.78%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.00%-1.15%-1.30%+0.36%+16.58%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.00%+2.34%+7.24%+11.33%+233.90%
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
0.00%-1.76%+2.59%-1.02%+5.53%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
4.8537 of 5 stars
3.24.04.23.91.91.71.9
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
4.4655 of 5 stars
2.33.03.34.12.91.71.9
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
1.6194 of 5 stars
1.43.01.70.01.90.03.1
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
4.9394 of 5 stars
3.43.04.24.02.02.52.5

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
2.46
Hold$175.8621.78% Upside
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
2.58
Moderate Buy$131.334.14% Upside
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
2.75
Moderate Buy$133.60-0.36% Downside
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
2.83
Moderate Buy$570.0513.18% Upside

Current Analyst Ratings

Latest UNH, NVO, JNJ, and MRK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/22/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$175.00
5/16/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$175.00
5/6/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$215.00
4/26/2024
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$142.00 ➝ $143.00
4/19/2024
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$545.00 ➝ $562.00
4/18/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$169.00 ➝ $170.00
4/18/2024
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$135.00
4/18/2024
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$160.00
4/17/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$168.00 ➝ $167.00
4/17/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$180.00 ➝ $170.00
4/17/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$181.00 ➝ $175.00
(Data available from 5/28/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$85.16B4.08$13.42 per share10.76$28.57 per share5.05
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$60.12B5.31$2.96 per share42.56$14.85 per share8.49
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$33.71B17.85$2.97 per share45.18$3.45 per share38.86
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
$371.62B1.25$29.51 per share17.07$102.08 per share4.93

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$35.15B$16.049.0013.222.4445.26%36.70%15.07%7/18/2024 (Estimated)
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$365M$0.90140.1212.711.663.76%14.05%5.24%8/6/2024 (Estimated)
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$12.15B$2.9046.2330.891.4036.56%91.70%29.86%8/8/2024 (Estimated)
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
$22.38B$16.3630.7916.261.474.05%26.50%8.60%7/12/2024 (Estimated)

Latest UNH, NVO, JNJ, and MRK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/2/2024Q1 2024
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.77$0.83+$0.06$0.83$9.23 billion$9.52 billion
4/25/2024Q1 2024
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$1.94$2.07+$0.13$2.27$15.21 billion$15.78 billion    
4/16/2024Q1 24
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$2.64$2.71+$0.07$3.22$21.39 billion$21.38 billion    
4/16/2024Q1 24
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
$6.63$6.91+$0.28$15.35$99.23 billion$99.80 billion    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$4.963.43%+5.70%30.92%63 Years
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$3.082.44%+6.08%342.22%13 Years
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$1.330.99%+16.52%45.86%1 Years
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
$7.521.49%+14.71%45.97%14 Years

Latest UNH, NVO, JNJ, and MRK Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/16/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
quarterly$1.243.36%5/20/20245/21/20246/4/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.36
1.17
0.94
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.77
1.25
0.99
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.17
0.70
0.50
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
0.69
0.85
0.85

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
69.55%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
76.07%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
11.54%
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
87.86%

Insider Ownership

CompanyInsider Ownership
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.16%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.09%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.07%
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
0.33%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
131,9002.41 billion2.40 billionOptionable
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
72,0002.53 billion2.53 billionOptionable
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
63,3704.49 billion4.48 billionOptionable
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
440,000920.39 million917.35 millionOptionable

UNH, NVO, JNJ, and MRK Headlines

Recent News About These Companies

UnitedHealth Group (NYSE:UNH) Stock Price Down 0.9%
UnitedHealth Group (NYSE:UNH) Stock Price Down 1.7%
UnitedHealth Group (NYSE:UNH) Stock Price Down 0.5%
UnitedHealth Group (NYSE:UNH) Stock Price Down 0.7%

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Johnson & Johnson logo

Johnson & Johnson

NYSE:JNJ
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Merck & Co., Inc. logo

Merck & Co., Inc.

NYSE:MRK
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians, wholesalers, government entities, veterinarians, distributors, animal producers, farmers, and pet owners. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
Novo Nordisk A/S logo

Novo Nordisk A/S

NYSE:NVO
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
UnitedHealth Group logo

UnitedHealth Group

NYSE:UNH
UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older addressing their needs; Medicaid plans, children's health insurance and health care programs; and health and dental benefits, and hospital and clinical services, as well as health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage. The Optum Health segment provides care delivery, care management, wellness and consumer engagement, and health financial services patients, consumers, care delivery systems, providers, employers, payers, and public-sector entities. The Optum Insight segment offers software and information products, advisory consulting arrangements, and managed services outsourcing contracts to hospital systems, physicians, health plans, governments, life sciences companies, and other organizations. The Optum Rx segment provides pharmacy care services and programs, including retail network contracting, home delivery, specialty and community health pharmacy services, infusion, and purchasing and clinical capabilities, as well as develops programs in the areas of step therapy, formulary management, drug adherence, and disease/drug therapy management. UnitedHealth Group Incorporated was founded in 1974 and is based in Minnetonka, Minnesota.